← Back to patent-cliff list
Amsulostat
Tier C — Watch / tradeAmsulostat
Syntara Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：LOXs
Indications (approved)：Myelofibrosis, Essential thrombocythaemia, Polycythaemia vera, Liver cancer, Hepatocellular carcinoma
Regional status
US
Phase II
2021-02-18
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Amsulostat?
Approved indications include: Myelofibrosis, Essential thrombocythaemia, Polycythaemia vera, Liver cancer, Hepatocellular carcinoma.
When does the Amsulostat patent expire?
No public expiry year is available for Amsulostat yet; this page updates once verified.
How do I get a quote for Amsulostat intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06